期刊
GENE THERAPY
卷 19, 期 2, 页码 121-126出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2011.164
关键词
age-related macular degeneration; angiogenesis; diabetic retinopathy; neovascularization; proliferative retinopathies
类别
资金
- National Eye Institute [EY05951, EY12609, EY10017]
- Juvenile Diabetes Research Foundation
Diseases complicated by abnormal growth of vessels or excessive leakage are the most prevalent cause of moderate or severe vision loss in developed countries. Recent progress unraveling the molecular pathogenesis of several of these disease processes has led to new drug therapies that have provided major benefits to patients. However, those treatments often require frequent intraocular injections, and despite monthly injections, some patients have a suboptimal response. Gene transfer of antiangiogenic proteins is an alternative approach that has the potential to provide long-term suppression of neovascularization (NV) and/or excessive vascular leakage in the eye. Studies in animal models of ocular NV have demonstrated impressive results with a number of transgenes, and a clinical trial in patients with advanced neovascular age-related macular degeneration has provided proof-of-concept. Two ongoing clinical trials, one using an adeno-associated viral (AAV) vector to express a vascular endothelial growth factor-binding protein and another using a lentiviral vector to express endostatin and angiostatin, will provide valuable information that should help to inform future trials and provide a foundation on which to build. Gene Therapy (2012) 19, 121-126; doi:10.1038/gt.2011.164; published online 10 November 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据